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Summary A phase 1 study of a new ribonucleotide reductase inhibitor, didox, was performed by
administration of escalating doses of the drug by slow i.v. injection. Thirty-four patients with unresponsive
metastatic carcinoma received the drug. There were 13 escalations of dosage, from a starting dose of
192mgm2 to 0gm-2. -Dose limiting toxicity was encountered at 7.5gm-2 where disturbances of hepatic
and renal function were observed, in addition to severe gastrointestinal toxicity.
Pharmacokinetic studies showed that a peak level of didox was achieved within 5 minutes of injection. At
1,728mgm-2 the data best fitted a 2 compartment open model, with a mean serum atl/2 of 5.2min, with a
/1t,/2 of 41.3min. Less than 10% of the drug was excreted unchanged in the urine and the majority of this
excretion was within 6h. Didox can therefore be safely given by slow i.v. injection at a dose of 6gm-2.
The biosynthesis of deoxyribonucleotides from ribo-
nucleotides is the first reaction in the biosynthetic pathway
that is specifically committed to DNA synthesis (Thelander
& Reichard, 1979). Thus, this reaction represents a prime
target for the development of cytotoxic drugs because it is
one of the rate controlling reactions in the biochemical
pathway that is specifically committed to DNA synthesis
(Elford et al., 1981).
In mammalian cells the pool size of deoxyribonucleotides
is not adequate to support DNA synthesis for more than a
brief period (Skoog et al., 1973). The enzyme ribonucleotide
reductase catalyses the reductive conversion of ribo-
nucleotides to deoxyribonucleotides with the level of this
enzyme closely correlated with the replicative rate of the cell
(Turner et al., 1968), with enzyme activity very low in non-
proliferating cells and exhibiting an increase on conversion
of the cell to a rapidly proliferating state (Elford et al.,
1970).
The only specific inhibitor of ribonucleotide reductase
presently available for clinical use is hydroxyurea (Thurman,
1964). However, the effectiveness of hydroxyurea is limited
because it is a weak inhibitor of ribonucleotide reductase
in vitro (Elford, 1968), and inhibitory levels are difficult to
maintain in vivo. Elford et al. have tested many analogues of
hydroxyurea for cytotoxic action, including many substituted
hydroxamic acids (Elford et al., 1979). One of the more
active of these compounds is didox (N,3-4trihydroxy-
benzamide), which has anti-neoplastic activity in L1210
leukaemia bearing female mice (Van't Riet et al., 1979) and
has been shown to be active in the NCI tumour panel and
was tested against L1210 and P388 leukaemias, B16 mela-
noma, Lewis Lung, Colo38, CDRF mammary tumour and
several human tumour xenografts (Elford & Van't Riet,
1985). Didox has been shown to exhibit greater inhibition of
ribonucleotide reductase compared to hydroxyurea (Elford et
al., 1979), with toxicity studies in mice showing an LD10 of
643mg/kg when given as a single dose (CRC Sponsored
Toxicity Report, 1984). Based on these experimental studies
a phase 1 study of didox in humans was performed.
Patients and methods
Patients with histologically confirmed metastatic carcinoma
which was progressive despite conventional first line therapy,
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if any existed, were studied. They were of good performance
status (ECOG Grade 0-2 [WHO, 1979]) and gave informed
consent. They had received no potentially myelosuppressive
therapy within 3 weeks of treatment and liver and renal
function were within normal limits prior to treatment.
Treatment was started at a dose of 192mgm-2, 10% of
the LD10 in mice for an intravenous dose. The dose was
escalated according to a modified Fibonacci scheme
(Goldsmith et al., 1975), with didox given as a single bolus
intravenously until the dose rose to 4gm-2. In view of
solubility difficulties at higher doses, the drug was thereafter
infused intravenously over 30min in 500ml of 0.5N dextrose
saline solution. Patients were treated every 3 weeks, with
escalation permitted 3 weeks after the previous dosing level,
with a minimum of 3 doses at each increment.
Blood samples were taken from an indwelling cannula at
varying times after injection of didox. Samples were stored
on ice and centrifuged at 3,000rpm for 5min at 4°C within
15min. Plasma was separated and stored at -20°C, with
aliquots of urine collected for 4 x 6 hourly periods after
injection of didox, and stored at -20°C until estimation of
didox levels were performed.
Analytic methods
Didox levels were estimated in plasma and urine by HPLC
using a Beckman/Altex 1OOA pump and stainless steel
column (25cm x 0.46cm) packed with u-Bondapack C18,
10 i particle size. Detection was achieved with an electro-
chemical detector, using a glassy carbon electrode with
applied potential of 800mV. Chromatograms were recorded
at 1 mV, and automatic injection, integration and step-
gradient were controlled by a Beckman/Altex programmer
Model 420. After addition of 2Mg internal standard, plasma
samples were extracted twice with 10ml ethyl acetate vortex-
ing for 20min. The organic phases were combined, evapor-
ated to dryness and reconstituted in 20% methanol prior to
injection. Separation of didox and internal standard was
achieved using a step-gradient elution system consisting of
the following buffers, at a flow rate of 1.5mlmin-1:
Buffers
1. 0.1 M sodium phosphate, 1 mM EDTA pH 3.5 for
2min.
2. As above +5% acetonitrile for 2min.
3. As above +10% acetonitrile for 7min.
The column was equilibrated with buffer 1 for 5min prior to
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adding the next sample. Retention times of 6min and
10.4min were observed for didox and internal standard
respectively. This method was found to have a detection
limit of 100ngml- 1, with an extraction efficiency of greater
than 80% and was linear up to 100pgml-1. Urine samples
were injected directly onto the column and eluted isocrati-
cally with 0.1% sodium phosphate, 1 mM EDTA, pH 3.5.
Following elution of didox and internal standard, the
column was washed with phosphate buffer containing 15%
acetonitrile and equilibrated for 7min with starting buffer
prior to injection of the next sample.
The plasma concentration-time profiles (1,728mgm 2;
n=6) were fitted to a 2 compartment open model by the
method of least squares using an 'in house' programme
based on the Marquhardt algorithm. The drug clearance and
steady state volume of distribution were calculated from the
microscopic rate constants; k10, k12 and k21.
Table II Toxicity of didox.
Symptom
Nausea
and
vomiting
Diarrhoea
LFT's
Bilirubin
Results
Patient details are shown in Table I. Thirty-four patients
were entered into the trial with a mean age of 56 years
(range 37-74). There were 23 male and 11 female patients.
All the patients had evidence of metastatic disease but were
of good performance status, all being self caring (ECOG
scale 0-2). The majority of patients had carcinoma of the
bronchus or carcinoma of unknown origin, with 13 patients
having received previous chemotherapy.
Eleven patients had only one injection of didox, treatment
being stopped because of progressive disease in the majority
of cases. Fourteen patients had 2 courses, 7 had 3 courses
and 2 had 4 courses of didox. There were 13 increments of
dosage and the highest dosage achieved was lOgm-2. No
clinical responses were observed at any dosage level.
Minor toxicity was initially noted at 2,304mgm 2
(Table II), with severe nausea and vomiting almost universal
above 7gm-2. Abnormalities of liver function were dose
limiting at doses at 7.5gm-2 and above. The only abnor-
mality of liver function seen at lower doses was elevated
alkaline phosphatase, but at higher doses increases in trans-
aminases and bilirubin were seen, with no evidence of
haemolysis.
Difficulty and delay in passing urine were the major renal
toxicities, although transient elevations in urea were
observed in 2 patients receiving 7,500mgm-2 and one
patient at 9,500mgm .2 One patient who died 4 days after
receiving didox was noted to have abnormal renal and liver
function tests. Autopsy revealed the presence of diffuse
tumour infiltration of the liver, but the kidneys were normal
histologically. All other hepatic and renal toxicities were
reversible. Severe diarrhoea (grade 4) was noted in 2
patients. This commenced prior to the completion of the
didox infusion and stopped within 6h. One of these patients,
who received 7.5gm-2 became severely hypotensive imme-
diately following the didox infusion. The patient was anuric
for 8h following this and developed transient abnormalities
Table I Patient details.
Number 34 (23M:11F)
Mean age (range) 56 (37-74)
Previous chemotherapy 13
Histology Adenocarcinoma U.O. 9
Colorectal 7
Melanoma 3
Gastric 2
Leiomyosarcoma 2
Anaplastic ca 2
Lung-Squamous 3
Adeno 2
SCLC I
Emb. rhabdo 1
Liposarcoma 1
Ampulla vater 1
AST
Drug dose
mgm-2
2,304
3,072
3,840
4,800
6,000
7,000
7,500
9,500
10,000
>7,500
4,800
6-7,000
7,500
9,500
10,000
Toxicity (WHO grade)
No. courses 1 2 3 4
8
3
4
6
4
1
10
I
1
2
6
5
10
I
I
- 1
-2 6
- 2
1 2
- 2
. 7,000 57
.7,500 12
Alk phos
Renalfunction
Urea
<3,000
3-6,000
>7,000
39
17
13
2
.7,500 12 4
in renal function tests, although these settled within 24h. An
increase in white cell count was observed in 4 patients
following didox, with total counts in excess of 20 x 109 1-
seen, but these increases were not related to the dose of
didox. None of these patients were receiving corticosteroids
and none had clinical symptoms suggestive of infection.
Peak levels of didox in the plasma were attained within
5min of injection. At the first dose of 192mgm 2 peak
levels of 8.8pgm- were recorded, and at the highest dose at
which samples were taken (7.5gm 2) peak levels of
166pgml-1 were achieved. More detailed information was
obtained at 1,728mgm 2 (n=6) as shown in Figure 1. The
data was appropriately fitted by a 2 compartment open
model. Drug clearance and steady state volume of distribu-
tion were calculated from the microscopic rate constants;
k10, k12 and k21 as shown in Table III. There was minimal
variation in plasma didox concentrations between patients as
is shown in Figure 1, and these levels were dose related as
illustrated in Figure 2. Less than 10% of the administered
dose of didox was excreted unchanged in the urine, with the
majority of this excretion within the first 6h (data not
shown).
Discussion
A phase 1 study of didox, a novel inhibitor of ribonucleotide
reductase, was performed. Toxicity was minor below
7gm 2, but severe dose limiting organ toxicity was initially
encountered at 10gm-2, but on reduction of the didox
dosage similar toxicities were observed at 7.5gm 2 The
major dose limiting toxicity was hepatic, although whether
this toxicity related to the peak level of drug or area under
the curve exposure (AUC) remains unclear. Renal toxicity
was observed in some patients although its aetiology remains
unclear. It would seem unlikely to be related to solubility of
the drug, as at doses greater than 4gm 2 didox was
dissolved in a large volume of fluid, and all administrations
were via a bacteriological filter. In these patients the renal
toxicity would appear to be predominantly pre-renal,
although a renal component could not be completely
excluded.
The levels of didox achieved in the plasma were dose
related and relatively constant between patients. At a dose of
1,728 mgm2, didox has rapid a and ,B half lives of 5.2 and
I
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Table III Pharmacokinetic parameters derived from a 2 compartment model fitted
to plasma concentration data at 1,728 mgm-2 (n=6). The results are expressed as
mean +1 s.d..
Steady state Area under
Total body volume of tl/2 tt12 the curve
Clearance distribution a ,B (O-oo)
(Imin-1m-2) (lm-2) (min) (min) (ml-1minn-2)
0.71 +0.19 27.9 +6.2 5.2+2.8 41.3+ 18.6 2,674+ 1,022
10
L
E
X 1
0.1.,.
o 1100 200
Time (min)
Figure I Plasma didox levels as measured in patients receiving
1,728 mgm-2 Each symbol represents a separate patient.
x
0
E
0.1.,.I
o 1100 200
Time (min)
Figure 2 Plasma didox levels as measured in a single patient
following administration of didox at 3 different doses:
- 1,344mgm-2
*- 1,728 mgm-2
*-2,304mgm-2
41.3 min respectively, with the data best fitted by a 2
compartment open model. Peak plasma levels at this dose
are approximately 300,M, and these levels correspond
favourably with the levels used in experimental systems. In
an enzyme study 30pM didox was shown to cause 50%
inhibition of the target enzyme, and in vitro concentrations
of 100 uM or less have been shown to be growth inhibitory in
a number of cell lines. These experiments have been per-
formed using continuous drug exposure, however, and the
didox levels achievable clinically using prolonged infusions
will be of interest. The 3 major metabolites formed in rats
are 3,4-dihydroxybenzamide, 3-hydroxy-4-methoxybenzo-
hydroxamic acid and 3-methoxy-4-hydroxy-
benzohydroxamic acid (Van't Riet, personal communica-
tion). The metabolism in man is unknown, although less
than 10% of the dose is excreted unchanged in the urine.
The maximum tolerated dose of didox given by bolus
injection in this study was 6gm 2, although the optimal
scheduling of the drug remains unclear. Hydroxyurea, the
only ribonucleotide reductase inhibitor in clinical use, has
previously been shown to be effective by prolonged 42 hour
infusion with reduced toxicity (Veale et al., 1987). It is
intended to further evaluate didox in phase 1 studies using
alternative schedules such as 36h infusions or daily times 5
injections.
Didox may be of value in combination with other cyto-
toxic drugs, particularly with anti-metabolites, as it is known
to deplete the pools of all deoxyribonucleotides by over 50%
(Elford et al., 1981), whereas hydroxyurea only depleted
pools of dGTP and dATP (Thelander & Reichard 1979). In
addition didox has been shown to act synergistically with
doxorubicin and cyclophosphamide in murine tumours
(Elford et al., 1984).
No responses were seen in 34 patients, but only 3 patients
received more than 1 course at doses of 6gm-2 or greater,
and it should be emphasised that the tumour types treated in
this study are generally considered unresponsive to chemo-
therapy. Therefore, despite the apparent lack of activity,
didox is worthy of further study in view of its potency for
the inhibition of the target enzyme (Elford et al., 1970).
We thank the nursing staff on the oncology wards at Newcastle
General Hospital for their support in this study. Didox was supplied
through the CRC Phase 1 Committee, and we are grateful to Dr B.
Van't Riet for synthesis of the compound.
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